PT - JOURNAL ARTICLE AU - Mari, Alfredo AU - Roloff, Tim AU - Stange, Madlen AU - Søgaard, Kirstine K. AU - Asllanaj, Erblin AU - Tauriello, Gerardo AU - Alexander, Leila Tamara AU - Schweitzer, Michael AU - Leuzinger, Karoline AU - Gensch, Alexander AU - Martinez, Aurélien AU - Bielicki, Julia AU - Pargger, Hans AU - Siegemund, Martin AU - Nickel, Christian H. AU - Bingisser, Roland AU - Osthoff, Michael AU - Bassetti, Stefano AU - Sendi, Parham AU - Battegay, Manuel AU - Marzolini, Catia AU - Seth-Smith, Helena M.B. AU - Schwede, Torsten AU - Hirsch, Hans H. AU - Egli, Adrian TI - Global surveillance of potential antiviral drug resistance in SARS-CoV-2: proof of concept focussing on the RNA-dependent RNA polymerase AID - 10.1101/2020.12.28.20248663 DP - 2021 Jan 01 TA - medRxiv PG - 2020.12.28.20248663 4099 - http://medrxiv.org/content/early/2021/01/04/2020.12.28.20248663.short 4100 - http://medrxiv.org/content/early/2021/01/04/2020.12.28.20248663.full AB - Antiviral treatments for COVID-19 have involved many repurposed drugs. Currently, SARS-CoV-2 RNA-dependent RNA polymerase (RdRp, encoded by nsp12-nsp7-nsp8) has been targeted by numerous inhibitors with debated clinical impact. Among these, remdesivir has been conditionally approved for the treatment of COVID-19 patients. Although the emergence of antiviral resistance, an indirect proxy for antiviral efficacy, poses a considerable healthcare threat, an evolutionary perspective on emerging resistant mutants is still lacking.Here we show that SARS-CoV-2 RdRp is under purifying selection, that potential escape mutations are rare, and unlikely to lead to viral fitness loss.In more than 56,000 viral genomes from 105 countries dating from December 2019 to July 2020 we found negative selective pressure affecting nsp12 (Tajima’s D = −2.62), with potential antiviral escape mutations in only 0.3% of sequenced genomes. Those affected known key residues, such as Nsp12:Val473 and Nsp12:Arg555. Of the potential escape mutations found globally, in silico structural models show that this rarely implies loss of stability in RdRp. No potential escape mutation were found in our local cohort of remdesivir treated patients from the first wave (n=8). Our results indicate that RdRp is a suitable drug target, and that remdesivir does not seem to exert high selective pressure. Our study could be the starting point of a larger monitoring effort of drug resistance throughout the COVID-19 pandemic. We recommend the application of repetitive genome sequencing of SARS-CoV-2 from patients treated with antivirals to provide early insights into the evolution or antiviral resistance.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04323761, NCT04351503Funding StatementNo dedicated funding was received for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted according to good laboratory practice and in accordance with the Declaration of Helsinki and national and institutional standards and was approved by the ethical committee (EKNZ: Ethikkommission Nordwest- und Zentralschweiz, Hebelstrasse 53, 4056 Basel, https://www.eknz.ch/) (Authorisation EKNZ 2020-00769). The clinical trial accession numbers are NCT04323761 and NCT04351503 (clinicaltrials.gov).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenome assemblies from the Basel open cohort were submitted to GISAID. Amplicon sequences from the remdesivir treated patients are available upon request.